Initial Beneficial Ownership · 3
TransCode Therapeutics, Inc.
RNAZNASDAQEQUITYCurrent
Initial Beneficial Ownership
Structured filing — 3
tm2625857-1_3seq1.xml
Filing details
- Report period
- 2026-09-10
- Issuer
- Transcode Therapeutics, Inc.
- Issuer CIK
- 0001829635
- Trading symbol
- RNAZ
- No securities owned
- Checked
Reporting owner 1
- Name
- Tattory John A
- Reporting owner CIK
- 0001499834
- Relationship
- Officer
- Officer title
- Interim CFO
- Address
- C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON, MA, 02109
Remarks
Exhibit 24: Power of Attorney
Signature 1
- Signed
- /s/ Philippe P. Calais, Attorney-in-Fact
- Date
- 2026-09-21
Filed exhibits
- EXHIBIT 24 ↗tm2625857d1_ex24.htm
Company context
TransCode is a clinical-stage company pioneering immuno-oncology and RNA therapeutics for treatment of high risk and advanced cancers We possess a diversified pipeline of therapeutic candidates, including two clinical stage assets, TTX-MC138, an antisense inhibitor of an oncogenic microRNA and Seviprotimut-L, a cancer vaccine. We also possess an oncolytic immunotherapy platform and three TTX-based pre-clinical stage assets.
Current securities
Recent company filings
- Other EventsOct 28, 2026
- Entry into a Material Definitive Agreement · Triggering Events That Accelerate or Increase a Direct Financial ObligationOct 1, 2026
- Other EventsSep 28, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 11, 2026
- 10-Q filingAug 14, 2026